NCT05957510 2024-02-22
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
Clinical Trials
63 trialsNCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05901584 2023-06-18
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Unknown
NCT03568097 2023-06-02
PAVE
Hellenic Cooperative Oncology Group
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05668767 2022-12-30
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Beijing Chest Hospital
Phase 2 Unknown
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05354700 2022-05-04
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2 Unknown
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT04660097 2022-04-12
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT01441349 2022-04-06
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05299255 2022-03-28
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT04985201 2021-08-09
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04698941 2021-07-29
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04740021 2021-02-05
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
Taizhou HoudeAoke Biomedical Co., Ltd.
Phase 2 Unknown
NCT02171325 2021-02-03
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT02337712 2021-01-27
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04683198 2020-12-24
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
ChineseAMS
Phase 2 Unknown
NCT04675697 2020-12-19
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT04647357 2020-11-30
A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04620837 2020-11-09
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
ChineseAMS
Phase 2 Unknown
NCT04501029 2020-08-06
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
Lee's Pharmaceutical Limited
Phase 2 Unknown
NCT03389087 2020-07-10
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03904719 2020-07-09
CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
AnewPharma
Phase 2 Unknown
NCT04453930 2020-07-01
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03983759 2020-06-11
Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT04314297 2020-03-19
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03585998 2020-03-02
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Samsung Medical Center
Phase 2 Unknown
NCT03613597 2020-02-05
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
Guizhou Medical University
Phase 2 Unknown
NCT03613753 2020-02-05
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
Guizhou Medical University
Phase 2 Unknown
NCT03700359 2019-11-29
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT04128800 2019-10-16
Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04056949 2019-08-14
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
Peking Union Medical College
Phase 2 Unknown
NCT02605811 2019-03-28
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
Guangzhou Medical University
Phase 2 Unknown
NCT03841136 2019-03-28
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
Fudan University
Phase 2 Unknown
NCT03780283 2018-12-21
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
First Hospital of Shijiazhuang City
Phase 2 Unknown
NCT03781869 2018-12-20
Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase 2 Unknown
NCT03732846 2018-11-07
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03135977 2017-12-07
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT02995187 2017-09-07
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
ChineseAMS
Phase 2 Unknown
NCT03219762 2017-07-26
Nabster
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT02980809 2016-12-02
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
First Hospitals affiliated to the China PLA General Hospital
Phase 2 Unknown
NCT02906384 2016-10-10
Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)
Zhejiang Cancer Hospital
Phase 2 Unknown